$30.66 $0.38 (1.2%)

02:05 PM EST on 02/19/20

LeMaitre Vascular, Inc. (NASDAQ:LMAT)

CAPS Rating: 4 out of 5

The Company is a medical device company that develops, manufactures and markets medical devices for the treatment of peripheral vascular disease.

Current Price $30.66 Mkt Cap $605.3M
Open $30.36 P/E Ratio 33.45
Prev. Close $30.28 Div. (Yield) $0.34 (1.1%)
Daily Range $29.99 - $30.83 Volume 62,812
52-Wk Range $28.00 - $38.64 Avg. Daily Vol. 127,123

Caps

How do you think NASDAQ:LMAT will perform against the market?

Add Stock to CAPS Watchlist

All Players

46 Outperform
2 Underperform
 

All-Star Players

12 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:LMAT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

ATrain (76.44)
Submitted October 03, 2017

Hidden gem in healthcare equipment. Focuses on niche products that large companies would not care about. Steadily introduces new products through R&D and has steady acquisitions. They are also debt free, so recession shouldn't hurt them.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

Recent Community Commentary

Read the most recent pitches from players about LMAT.

Recs

0
Member Avatar LazyHarlequin (96.32) Submitted: 10/5/2018 10:13:42 AM : Underperform Start Price: $29.19 NASDAQ:LMAT Score: +11.90

ON 10/5/18 down $6.13 to $29.83. Options available.

Recs

1
Member Avatar ATrain (76.44) Submitted: 10/3/2017 6:35:53 PM : Outperform Start Price: $36.67 NASDAQ:LMAT Score: -50.32

Hidden gem in healthcare equipment. Focuses on niche products that large companies would not care about. Steadily introduces new products through R&D and has steady acquisitions. They are also debt free, so recession shouldn't hurt them.

Recs

0
Member Avatar TMFEBCapital (92.52) Submitted: 7/10/2017 2:24:24 PM : Outperform Start Price: $27.20 NASDAQ:LMAT Score: -26.76

Small cap, debt-free company growing top-line 10%, bottom-line 20%, by targeting niche vascular surgery products, including biologics. 18% owned by founder aligns perfectly with investors. Tailwinds due to aging baby boomers support U.S. revenue, where margins are best. Company has not relied on price increases for growth (<5% annually). Using weakness on downgrades today to add.

Leaderboard

Find the members with the highest scoring picks in LMAT.

Score Leader

TrackJesupLamont

TrackJesupLamont (< 20) Score: +398.46

The Score Leader is the player with the highest score across all their picks in LMAT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
roosterus 43.55 9/24/2007 Outperform 3W $5.80 +429.55% +134.11% +295.44 0 Comment
razormd 66.01 9/24/2007 Outperform 5Y $5.91 +419.97% +133.16% +286.82 1 Comment
swr1111 < 20 12/6/2007 Outperform NS $5.96 +415.28% +138.76% +276.52 1 Comment
lionstan 87.43 9/25/2007 Outperform 5Y $6.02 +409.93% +134.58% +275.35 0 Comment
pituach < 20 10/9/2007 Outperform NS $6.32 +385.49% +128.46% +257.03 0 Comment
Schneezy 28.40 10/25/2010 Outperform 1Y $5.76 +433.09% +184.30% +248.79 0 Comment
MooFoo < 20 10/28/2013 Outperform 5Y $7.04 +335.95% +92.57% +243.38 0 Comment
orobica 30.02 7/25/2014 Outperform 5Y $7.47 +311.07% +71.26% +239.81 0 Comment
Playa14 < 20 1/29/2015 Outperform 5Y $7.52 +308.22% +69.35% +238.87 0 Comment
gunterle 67.56 3/4/2015 Outperform 5Y $7.93 +287.16% +61.12% +226.04 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for LMAT.